Sign up for Trump’s Return, a newsletter featuring coverage of the second Trump presidency. Donald Trump, always one to tout his knack for dealmaking, declared on ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

Pfizer Ventures announced its investment in Vibrant Therapeutics, a clinical-stage biotechnology company. The $61 million financing round included new investor Apricot Capital, with participation from ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...